Shares of ImmunityBio (IBRX) have gained 41.1% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.25 indicates a potential upside of 184.4%.The average comprises three short-term price targets ranging from a low of $4.75 to a high of $30, with a standard deviation of $13.74. While the lowest estimate indicates ...